Drug intelligence / Profile preview

Lactobacillus rhamnosus LOCK 0900

Development stage: Unknown
Lead developer: Institute of Immunology and Experimental Therapy
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus rhamnosus ŁOCK 0900 is a specific, patented strain of probiotic bacteria developed and manufactured by the Polish company Biomed S.A. [2, 5]. It was previously classified as Lactobacillus casei ŁOCK 0900 [4, 6]. This strain is not marketed as a standalone product but is a key component of a three-strain probiotic mixture sold under the brand name Latopic® [1, 2]. This mixture, which also contains Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919, is intended for the dietary management of atopic dermatitis and food allergies, particularly in children [3, 4, 5]. Clinical studies have evaluated the efficacy of this combination in alleviating symptoms of atopic dermatitis by modulating the gut microbiome and the host's immune system to promote anti-allergic mechanisms [2, 3, 5, 7].

Other names: Lactobacillus casei LOCK 0900

Beyond the preview

Go deeper on Lactobacillus rhamnosus LOCK 0900.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus rhamnosus LOCK 0900.

Explore the full profile